Enterome raises €5.5m funding to validate biomarkers; Fasting blood glucose signals depression in elderly;

> Paris-based biomarker company Enterome has raised €5 million ($6.6 million) to validate its biomarkers and help move them toward diagnostic tests. Article

> A panel of 10 serum biomarkers could support CT screening in diagnosis of lung cancer in high-risk people. Article

> Fasting blood glucose signals more than diabetes; it could diagnose depression in elderly people. Article (sub. req.)

> The leukocyte-based biomarker BORIS is in a trial as a potential early breast cancer biomarker in women with high familial risk of the disease. Article

> Qiagen and the Bio-X Center of Shanghai Jiao Tong University are to set up a translational medicine base in Shanghai; the projects will include biomarker validation. Article

> An ER stress biomarker could pick up diabetes before symptoms start, if mouse model findings transfer across to the clinic. Press release

> Soluble CD14, a biomarker in babies' umbilical cord blood, could signpost their risk of cough and wheeze at one year. Article

> A new method to measure beta amyloid, using flow cytometry, could help develop Alzheimer's disease drugs and diagnostics. Press release

> Magnetic resonance imaging can "see" the oncometabolite 2-hydroxyglutarate; this technique could have potential in brain tumor diagnosis. Press release | Abstract

> Troponin-I assay could predict risk of cardiovascular death up to 15 years in the future. Press release

> New autism mouse model has suggested a link between early disruptions in serotonin signaling in the brain and autism spectrum disorder. Press release

> Levels of granulocyte colony-stimulating factor (G-CSF) could be a biomarker for the severity of stroke. Abstract

And Finally… State wealth could be linked with cardiac biomarkers. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.